Publication

Article

Pharmaceutical Technology

Pharmaceutical Technology-11-02-2003
Volume27
Issue 11

Routine Sample Size for a Retest Procedure

Author(s):

Jeffrey D. Hofer

This article discusses a straightforward approach that scientists may use to descide how many nonsuspect restest results are required to provide sufficient evidence to overcome an initial suspect result.

External Link - article-75176.pdf

Articles in this issue
FDA Will Drive Changes for Contract Business
In the Spotlight--December
Novemember 2003
FDA Seeks Risk-Based Inspection Program
Routine Sample Size for a Retest Procedure
November 2003
Aseptic Processing Guidelines and Innovative Engineering Boost Appeal of Barrier Isolators
Clearing Regulatory Hurdles
Improving Protein Capture for Transgenic Drug Processing

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Subscribe Now!
Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Related Content
Futuristic health tech. A smartwatch projects a holographic health dashboard, providing real-time body analytics and vital signs monitoring anytime, anywhere. | Image Credit: © woravut - stock.adobe.com
August 5th 2025

How FDA’s ISTAND Initiative Supports Innovative Tools in Drug Discovery and Development

Patrick Lavery
The program has been transitioned to a permanent pathway that is designed to support innovative tools like artificial intelligence, wearables, and biomarkers in drug development and trials.
Drug Solutions Podcast: Sustainable Solutions for Biopharma
August 5th 2025

Drug Solutions Podcast: Sustainable Solutions for Biopharma

Patrick Lavery
In this podcast episode, we discuss sustainable approaches to such equipment and materials as medical propellants, flow sensor technology, and walk-in chambers, plus the critical role of women in elevating and accelerating development in these areas.
Site Logo
August 5th 2025

Accelerate drug development with innovative 360˚ CDMO and CRO solutions: A comprehensive guide to streamlining drug development and reducing time to market

Patheon
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
August 5th 2025

Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries

Patrick Lavery
In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Site Logo
August 5th 2025

Value reimagined: Unlocking ROI and efficiency in drug development

Patheon
White House | Image Credit: © Zack Frank - stock.adobe.com
August 5th 2025

Trump Sends Letters to 17 Leading Pharma Companies Outlining Most-Favored-Nation Drug Pricing Protocol

Patrick Lavery
If action is not taken within 60 days, the White House said it would “deploy every tool in our arsenal” to improve drug pricing practices for American patients.